A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status

Oncology

Volumn 77, Issue 6, 2010, Pages 349-357

  Im, Chong Kun ^a   Rha, Sun Young ^a   Jeung, Hei Cheul ^a   Jeong, Jaeheon ^a   Lee, Soo Hyeon ^a   Noh, Sung Hoon ^b   Roh, Jae Kyung ^a   Chung, Hyun Cheol ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Advanced gastric cancer; Paclitaxel monotherapy; Poor performance status; Weekly paclitaxel

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHLORPHENIRAMINE MALEATE; CIMETIDINE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMACH CANCER; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; MIDDLE AGED; MORTALITY; PROGNOSIS; STOMACH TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; STOMACH NEOPLASMS;

EID: 72049113118     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000265941     Document Type: Article

References (34)

1. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41. (Pubitemid 23182046)
2. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587-591.
3. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168. (Pubitemid 27112884)
4. Jo JC, Lee JL, Ryu MH, Sym SJ, Lee SS, Chang HM, Kim TW, Lee JS, Kang YK: Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis. Jpn J Clin Oncol 2007; 37: 936-941.
5. Park SH, Kim YS, Hong J, Park J, Nam E, Cho EK, Shin DB, Lee JH, Lee WK, Chung M: Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study. Anticancer Drugs 2008; 19: 303-307.
6. Seo MD, Lee KW, Lim JH, Yi HG, Kim DY, Oh DY, Kim JH, Im SA, Kim TY, Lee JS, Bang YJ: Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. Jpn J Clin Oncol 2008; 38: 589-595.
7. Nguyen S, Rebischung C, Van Ongeval J, Flesch M, Bennamoun M, Andre T, Ychou M, Gamelin E, Carola E, Louvet C: Epirubicin- docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment. Bull Cancer 2006; 93:E1-E6.
8. Zhong H, Zhang Y, Ma S, Ying JE, Yang Y, Yong D, Hang X, Sun Q, Zhong B, Wang D: Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer. Anticancer Drugs 2008; 19: 1013-1018.
9. Jeung HC, Rha SY, Shin SJ, Ahn JB, Noh SH, Roh JK, Chung HC: A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. Br J Cancer 2007; 97: 458-463.
10. Cunningham D, Hole D, Taggart DJ, Soukop M, Carter DC, McArdle CS: Evaluation of the prognostic factors in gastric cancer: the effect of chemotherapy on survival. Br J Surg 1987; 74: 715-720. (Pubitemid 17108431)
11. Hsu CH, Yeh KH, Chen LT, Liu JM, Jan CM, Lin JT, Chen YC, Cheng AL: Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers. An effective and low-toxic regimen for patients with poor general condition. Oncology 1997; 54: 275-280.
12. Jeung HC, Rha SY, Kim YT, Noh SH, Roh JK, Chung HC: A phase II study of infusional 5- fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer. Oncology 2006; 70: 63-70.
13. Im CK, Jeung HC, Rha SY, Yoo NC, Noh SH, Roh JK, Chung HC: A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. Cancer Chemother Pharmacol 2008; 61: 315-321. (Pubitemid 350160330)
14. Shin SJ, Jeung HC, Ahn JB, Choi HJ, Cho BC, Rha SY, Yoo NC, Roh JK, Chung HC: Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. Cancer Chemother Pharmacol 2008; 61: 157-165. (Pubitemid 47512637)
15. Chang YF, Li LL, Wu CW, Liu TY, Lui WY, P'Eng FK, Chi CW: Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 1996; 77: 14-18. (Pubitemid 26002731)
16. Lorenzo I, Constenla M, Palacios P, Garcia- Arroyo FR, Fernandez I, Campos B, Salgado L, Carrete N: Docetaxel as single-agent treatment in elderly patients with advanced breast cancer. Clin Drug Investig 2005; 25: 249-256. (Pubitemid 40593612)
17. Penel N, Bui BN, Bay JO, Cupissol D, Ray- Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY: Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008; 26: 5269-5274.
18. Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y: Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006; 9: 14-18.
19. Hirabayashi M, Endoh K, Teramachi M, Okuda M, Yamaguchi K, Fukuda K, Tokuhisa H, Kagioka H, Nakai N, Nakade M: Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study. Lung Cancer 2004; 44: 355-362. (Pubitemid 38609444)
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
21. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997. (Pubitemid 46631401)
22. Ratnayake G, Cunningham D: Does combining docetaxel with cisplatin and fluorouracil improve clinical benefit in advanced gastroesophageal cancer? Nat Clin Pract Oncol 2008; 5: 132-133. (Pubitemid 351343586)
23. Smith IE, O'Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, Norton A, Ashley S: Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001; 19: 1336-1343. (Pubitemid 32202538)
24. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee JH, Tynan M, Moore M, Kies MS: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second- line therapy in advanced-stage IIIb/IV non-small-cell lung cancer. J Clin Oncol 2002; 20: 1335-1343. (Pubitemid 34182817)
25. Park JO, Kim SW, Ahn JS, Suh C, Lee JS, Jang JS, Cho EK, Yang SH, Choi JH, Heo DS, Park SY, Shin SW, Ahn MJ, Yun YH, Lee JW, Park K: Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 2007; 25: 5233-5239. (Pubitemid 350232255)
26. Lal R, Dickson J, Cunningham D, Chau I, Norman AR, Ross PJ, Topham C, Middleton G, Hill M, Oates J: A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor- resistant advanced colorectal cancer. J Clin Oncol 2004; 22: 3023-3031. (Pubitemid 41103713)
27. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez- Staub N, Louvet C, Andre T, Tabah-Fisch I, de Gramont A: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006; 24: 394-400. (Pubitemid 46630458)
28. Jeong J, Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB, Noh SH, Roh JK, Chung HC: Phase II study of combination chemotherapy of 5- fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. Ann Oncol 2008; 19: 1135-1140. (Pubitemid 351796339)
29. Yoshida S, Miyata Y, Ohtsu A, Boku N, Shirao K, Shimada Y: Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer. Gastric Cancer 2000; 3: 128-133. (Pubitemid 32182868)
30. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS: Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87: 236-242. (Pubitemid 30088655)
31. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF: Phase II study of taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998; 4: 269-274. (Pubitemid 28354929)
32. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, Catalano G: Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 1998; 9: 307-310. (Pubitemid 28241819)
33. Yamaguchi K, Tada M, Horikoshi N, Otani T, Takiuchi H, Saitoh S, Kanamaru R, Kasai Y, Koizumi W, Sakata Y, Taguchi T: Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 2002; 5: 90-95. (Pubitemid 34832243)
34. Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, Tong W, Norton L, Spriggs D: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15: 187-192. (Pubitemid 27020572)